Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

ypes of DLBCL, the activated B-cell (ABC) subtype and the germinal center (GC) subtype. We have enrolled 3 out of the planned 60 patients and expect to complete enrollment in the first quarter of calendar 2012. Other trials evaluating the combination of PCI-32765 with chemotherapy in DLBCL are under development.

A separate pilot study of PCI-32765 in patients with ABC subtype DLBCL is currently being conducted at the NIH Clinical Center. Thus far, 8 out of a planned 10 patients have been enrolled. While it is too early to report full results of this study, objective responses, including complete responses, have been observed. We anticipate that this study once completed will be submitted for presentation at the 2011 American Society of Hematology Meeting

-- Follicular Lymphoma (FL)
Updated results from the Phase IA study have shown an improvement in the objective response rate in follicular lymphoma. We are encouraged by this preliminary signal and are developing a Phase II program in this histology. We anticipate the initiation of a Phase II trial in follicular lymphoma in the first half of 2012.

-- Multiple Myeloma (MM)
Ongoing pre-clinical studies, both internally as well as through external collaborations, have suggested a vital role for Btk in both malignant plasma cells and osteoclasts, which are involved in the bone complications of this disease. Therefore, we believe that Btk represents a viable therapeutic target in MM, and we are developing a Phase II trial of PCI-32765 in MM, which we expect to initiate in early 2012.

"In February 2009 Pharmacyclics dosed the first patient with PCI-32765, a Bruton tyrosine kinase irreversible inhibitor. Bottom line, we have now dosed 230 patients across multiple hematologic histologies. The results have exceeded the expectations of most all involved to this point in time. We look forward to continued progress as well as playing a meaningful role in the comin
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... condition to the announced tender offer for all of the outstanding ... result of the waiver, the transaction is no longer conditional on ... January 24, 2014 following the currently scheduled expiration time, subject to ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
(Date:7/10/2014)... Huddersfield could help to improve the quality of some ... as butter, mayonnaise, yoghurt and fruit drinks and ... her work. , Katerina gained her MSc degree in ... she has embarked on research for a PhD. ... investigating the potential of carbohydrates extracted from the pods ...
(Date:7/10/2014)... review identifying the clinical indicators most strongly associated with ... of developing evidence-based guidelines for concussion diagnosis, prognosis, and ... Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... , Based on analysis of the best available research ...
(Date:7/10/2014)... For decades, health-conscious people around the globe have ... figuring this was one of the paths to good ... clinical trials of antioxidant supplements have repeatedly dashed the ... their cancer risk. Virtually all such trials have ... In fact, in several trials antioxidant supplementation has been ...
(Date:7/10/2014)... Researchers at sarcomas research group at the Bellvitge Biomedical ... (ICO) have been tested in 19 patients a new ... results, which indicate that the new treatment could stabilize ... week in the British Journal of Cancer ., ... tumor and complex since there are several subtypes. It ...
(Date:7/10/2014)... that a new drug could prove useful in treating small ... cancer. , Scientists from the Cancer Research UK Manchester Institute, ... Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, ... a drug known as AZD3965 - on small cell ... Clinical Cancer Research , also helps identify which patients ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:New drug active against most aggressive type of lung cancer cells 2
... baby to a 3D ultrasound imaging session offered by private ... advice has been offered by medical experts, in the wake ... of the unborn child. ,It is no longer news ... ultrasound machine in 2005, so that they could monitor their ...
... drugs have a high proportion of viral strains that can ... to a study published in the February 15th edition of ... Timothy J Wilkin of Weill-Cornell Medical College, New York, also ... (known as dual-tropic virus) had lower CD4 cell counts than ...
... Medical Center is one of the first medical centers ... Illinois, participating in a novel clinical trial to// determine ... form of severe coronary artery disease. ,The ... the first human, Phase II adult stem cell therapy ...
... prisoner, otherwise calm, had suddenly turned awry. Guards in ... Apparently, the prisoner had been consuming from a gallon ... ,The alarm regarding abuse of hand sanitizers was ... Control Center, Dr. Suzanne Doyon, who has sought to ...
... A review of data available on most of the ... the prevalence of Multiple Sclerosis// and Alzheimer’s diseases had ... one out of 1,000 people have multiple sclerosis (MS). ... higher than a comprehensive review from 1982. Whether this ...
... in Chicago has launched a leukaemia awareness campaign and ... suffering// from the disease. ,Steve Hill, a ... coming to know that Nikit Patel, the 22-year-old son ... diagnosed with acute myelogenous leukaemia (AML)., ,AML ...
Cached Medicine News:Health News:Mixed HIV Coreceptor Use Associated With Lower CD4 Count 2Health News:Mixed HIV Coreceptor Use Associated With Lower CD4 Count 3Health News:Mixed HIV Coreceptor Use Associated With Lower CD4 Count 4Health News:Potential for Adult Stem Cells to Repair Hearts Damaged Investigated 2Health News:Potential for Adult Stem Cells to Repair Hearts Damaged Investigated 3Health News:Incidence of Neurological Disorders on the Rise 2Health News:US Student Raising Funds For Cancer-Ridden Indian American 2
Clearview RSV is a simple, immunochromatographic assay to aid in the diagnosis of respiratory syncytial virus (RSV) infections in children less than 6 years and adults over age 60....
Clearview ULTRA FOB is a rapid, two-step immunochemical test for the detection of fecal occult blood....
... RTVue is an ultra-high speed, high resolution ... for retina imaging and analysis. ... Fourier-Domain Optical Coherence technology just emerging from ... The ultra-high speed and high ...
The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
Medicine Products: